- Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.
VIR Biotechnology is developing TCEs targeting EGFR for solid tumors, specifically testing treatments for non-small cell lung cancer and colorectal cancer.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
VIR Biotechnology is developing TCEs targeting EGFR for solid tumors, specifically testing treatments for non-small cell lung cancer and colorectal cancer.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
VIR Biotechnology
biotech company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Business WireVir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors Phase 1 clinical trial desi